27Jun2018How Are Biotech’s VCs Performing? Not As Well As You May Think/Luke Timmerman/1/All, Venture Capital27 Jun 2018Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.